Skip to main content
. 2020 Feb 19;2(2):203–209. doi: 10.1016/j.jaccas.2019.11.076

Figure 3.

Figure 3

Cardiac Magnetic Resonance Imaging

(A) Cardiac magnetic resonance imaging (MRI) 2 weeks following nivolumab rechallenge with no significant late gadolinium enhancement (LGE). (B) Cardiac MRI 6 weeks following nivolumab rechallenge with mild subepicardial LGE along the inferior and lateral walls of the left ventricle.